Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer. Philogen announces participation to the 10th World Congress of Melanoma...
NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned. PRESS RELEASE – 13/01/2021
Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nano particles. (see full press release). Siena (Italy), December 22nd, 2014.
Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference. Huntingdon Beach, California (USA), December 7th-11th, 2014.